当前位置:首页 > 报告详情

Baxter-J-P-Morgan-Conference-Presentation.pdf

上传人: 明**** 编号:1069740 2026-01-17 13页 1.53MB

1、44th Annual J.P.Morgan Healthcare Conference1Andrew HiderAndrew HiderPresident&Chief Executive OfficerJanuary 12,20262Safe Harbor StatementThis presentation includes forward-looking statements concerning the companys financial results(including the companys net leverage target and estimated timing c

2、onsiderations)and operational,business development and regulatory activities.These forward-looking statements are based on assumptions about many important factors,including the following,which could cause actual results to differ materially from those in the forward-looking statements:the companys

3、ability to achieve the intended benefits of its recent strategic actions,including the sale of the Kidney Care business,business strategy and development activities(including the acquisition Hill-Rom Holdings,Inc.and completion of related integration activities)and cost saving initiatives,or of futu

4、re long-term financial improvement goals;the impact of global economic conditions(including,among other things,changes in tariffs,taxation,trade policies and treaties,sanctions,embargos,export control restrictions,the potential for a recession,supply chain disruptions,inflation levels and interest r

5、ates,financial market volatility,banking crises,the war in Ukraine,the conflict in the Middle East and other geopolitical events,and the potential for escalation of these and other conflicts,the related economic sanctions being imposed globally in response to the conflicts and potential trade wars,g

6、lobal public health crises,pandemics and epidemics,or the anticipation of any of the foregoing,on the companys operations and on the companys employees,customers,suppliers,and foreign governments in countries in which the company operates and the companys ability to identify actions to mitigate the

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司概况**:Baxter是全球医疗健康企业,业务覆盖100+国家,年治疗患者3.5亿+,员工3.8万+,制造基地40+个(截至2025年底)。 2. **财务表现**:2025年第三季度(LTM)全球营收110亿美元(持续运营业务),其中美国25亿、国际30亿、医药业务52亿。 3. **战略重点**: - **去杠杆化**:目标2026年底净杠杆率降至3.0x,维持投资级信用评级。 - **资本配置**:优先投资核心平台与创新,增加增长型资本支出;维持季度分红。 - **业务优化**:通过Baxter GPS系统提升运营效率,聚焦增长与执行。 4. **风险提示**:涉及全球经济、监管变化、产品开发、供应链、网络安全等多重风险(详见原文)。
**Baxter战略重点?** **医疗风险有哪些?** **创新进展如何?**
客服
商务合作
小程序
服务号
折叠